◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Global Health Limited (MEDANTA) Revenue 2023–2026

Name: Global Health Limited (MEDANTA) revenue history 2023-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Global Health Limited annual revenue for fiscal 2026 was ₹43.2 billion, an increase of 18.7% from ₹36.4 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

MEDANTA Annual Revenue

Revenue (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹43.2B	₹36.4B	₹32.4B	₹26.8B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MEDANTA Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹13.0B	₹11.6B	₹11.2B	₹11.0B	₹10.3B	—	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

MAXHEALTH Revenue — Max Healthcare Institute Limited
MANIPALHOS Revenue — Manipal Health Enterprises Limited
FORTIS Revenue — Fortis Healthcare Limited
ASTERDM Revenue — Aster DM Quality Care Limited
NH Revenue — Narayana Hrudayalaya Limited
KIMS Revenue — Krishna Institute of Medical Sciences Limited

More MEDANTA metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All MEDANTA financial statements → Interactive MEDANTA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.